Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-006
- Development stage
- Phase 1
- Lead developer
- Vaxon Biotech
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VX-006 is a therapeutic cancer vaccine developed by VAXON Biotech. It targets three tumor-associated antigens: HER2 (receptor tyrosine-protein kinase erbB-2), MAGEA1 (melanoma-associated antigen 1), and TERT (telomerase reverse transcriptase). The mechanism of action involves antagonism or inhibition of these targets, aiming to stimulate an immune response against tumors expressing these antigens. The vaccine has been investigated primarily for the treatment of neoplasms, with clinical trials conducted in patients with solid tumors who are HLA-A*02 positive[1].
02
Targets
MAGEA1 (Melanoma-associated antigen 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TERT (Telomerase)
Beyond the preview
Go deeper on VX-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-006.